Skip to main content
NCBI home page
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1996 Jul;27:S282–S286.

A randomised study of ornidazole as a radiosensitiser in carcinoma of the cervix: long term results.

S Okkan 1, G Atkovar 1, I Sahinler 1, S Turkan 1, R Uzel 1
PMCID: PMC2149986  PMID: 8763898

Abstract

This paper presents long-term results of a randomised study of ornidazole as a radiosensitiser in locally advanced carcinoma of the cervix. A total of 76 patients were randomised and followed-up with a median of 85 months. All patients were treated with external and intracavitary irradiation. The 10 year actuarial local control rate was 61% in patients receiving ornidazole, compared with 50% for placebo group. This difference was not statistically significant. Ten year actuarial overall and disease-free survival rates were also similar in the two treatment groups. Although, when analysed by stage, there was a significant advantage in the local control (54% vs 15%; P = 0.044) and disease-free survival rates (37% vs 8%; P = 0.047) in ornidazole group for stage IIIB cases, its implication is obscure because of the small number of patients. In this study moderate and severe complication rates were found to be 30%. These results suggest that ornidazole seems to have relatively weak sensitisation and it may show a possibility of a marginal benefit with unconventional irradiation using relatively large radiation doses. However, the results are insufficient for a real gain in the probability of local tumour control and survival.

Full text

PDF
S282

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown J. M. Sensitizers and protectors in radiotherapy. Cancer. 1985 May 1;55(9 Suppl):2222–2228. doi: 10.1002/1097-0142(19850501)55:9+<2222::aid-cncr2820551426>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  2. Bush R. S. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys. 1986 Nov;12(11):2047–2050. doi: 10.1016/0360-3016(86)90146-x. [DOI] [PubMed] [Google Scholar]
  3. Cikarić S. Radiation therapy of cervical carcinoma using either HDR or LDR afterloading: comparison of 5-year results and complications. Sonderb Strahlenther Onkol. 1988;82:119–122. [PubMed] [Google Scholar]
  4. Dische S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother Oncol. 1985 Feb;3(2):97–115. doi: 10.1016/s0167-8140(85)80015-3. [DOI] [PubMed] [Google Scholar]
  5. Dische S. Radiotherapy and anaemia--the clinical experience. Radiother Oncol. 1991;20 (Suppl 1):35–40. doi: 10.1016/0167-8140(91)90184-i. [DOI] [PubMed] [Google Scholar]
  6. Hamberger A. D., Unal A., Gershenson D. M., Fletcher G. H. Analysis of the severe complications of irradiation of carcinoma of the cervix: whole pelvis irradiation and intracavitary radium. Int J Radiat Oncol Biol Phys. 1983 Mar;9(3):367–371. doi: 10.1016/0360-3016(83)90298-5. [DOI] [PubMed] [Google Scholar]
  7. Joslin C. A., Kilara G., Khoury G. Influence of HDR fractions and dose on the 5-year results and complications of cervix cancer. Sonderb Strahlenther Onkol. 1988;82:100–105. [PubMed] [Google Scholar]
  8. Kuipers T. Dosimetry and complication rate in the treatment of cervix carcinoma with external irradiation and brachytherapy. Sonderb Strahlenther Onkol. 1988;82:127–131. [PubMed] [Google Scholar]
  9. Leibel S., Bauer M., Wasserman T., Marcial V., Rotman M., Hornback N., Cooper J., Gillespie B., Pakuris E., Conner N. Radiotherapy with or without misonidazole for patients with stage IIIB or stage IVA squamous cell carcinoma of the uterine cervix: preliminary report of a Radiation Therapy Oncology Group randomized trial. Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):541–549. doi: 10.1016/0360-3016(87)90069-1. [DOI] [PubMed] [Google Scholar]
  10. Okkan S., Uzel R. The radiosensitizing effect of ornidazole in hypoxic mammalian tissue: an in vivo study. Int J Radiat Oncol Biol Phys. 1982 Oct;8(10):1735–1739. doi: 10.1016/0360-3016(82)90295-4. [DOI] [PubMed] [Google Scholar]
  11. Okkan S., Yazici Z., Uzel R., Akçasu A., Turkan S., Hacibekiroğlu M., Olgun P., Egehan I. Use of ornidazole in fractionated radiotherapy: dose tolerance, serum and tumour tissue concentration. Radiother Oncol. 1986 Apr;5(4):295–301. doi: 10.1016/s0167-8140(86)80178-5. [DOI] [PubMed] [Google Scholar]
  12. Orton C. G., Seyedsadr M., Somnay A. Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1425–1434. doi: 10.1016/0360-3016(91)90316-v. [DOI] [PubMed] [Google Scholar]
  13. Overgaard J., Bentzen S. M., Kolstad P., Kjoerstad K., Davy M., Bertelsen K., Mäntyla M., Frankendal B., Skryten A., Löftquist I. Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1069–1072. doi: 10.1016/0360-3016(89)90918-8. [DOI] [PubMed] [Google Scholar]
  14. Patel F. D., Sharma S. C., Negi P. S., Ghoshal S., Gupta B. D. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):335–341. doi: 10.1016/0360-3016(94)90055-8. [DOI] [PubMed] [Google Scholar]
  15. Perez C. A., Breaux S., Bedwinek J. M., Madoc-Jones H., Camel H. M., Purdy J. A., Walz B. J. Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications. Cancer. 1984 Jul 15;54(2):235–246. doi: 10.1002/1097-0142(19840715)54:2<235::aid-cncr2820540210>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  16. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Selke P., Roman T. N., Souhami L., Freeman C. R., Clark B. G., Evans M. D., Pla C., Podgorsak E. B. Treatment results of high dose rate brachytherapy in patients with carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):803–809. doi: 10.1016/0360-3016(93)90452-2. [DOI] [PubMed] [Google Scholar]
  18. Sherrah-Davies E. Morbidity following low-dose-rate selectron therapy for cervical cancer. Clin Radiol. 1985 Mar;36(2):131–139. doi: 10.1016/s0009-9260(85)80095-7. [DOI] [PubMed] [Google Scholar]
  19. Stehman F. B., Bundy B. N., Thomas G., Keys H. M., d'Ablaing G., 3rd, Fowler W. C., Jr, Mortel R., Creasman W. T. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol. 1993 Aug;11(8):1523–1528. doi: 10.1200/JCO.1993.11.8.1523. [DOI] [PubMed] [Google Scholar]
  20. Urtasun R., Band P., Chapman J. D., Feldstein M. L., Mielke B., Fryer C. Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med. 1976 Jun 17;294(25):1364–1367. doi: 10.1056/NEJM197606172942503. [DOI] [PubMed] [Google Scholar]
  21. Uzel R., Okkan S., Töre G., Koca S. Results and complications of high dose rate intracavitary radiotherapy compared with conventional dose rate in carcinoma of the cervix. Sonderb Strahlenther Onkol. 1988;82:132–136. [PubMed] [Google Scholar]
  22. Vahrson H., Römer G. 5-year results with HDR afterloading in cervix cancer: dependence on fractionation and dose. Sonderb Strahlenther Onkol. 1988;82:139–146. [PubMed] [Google Scholar]
  23. Watson E. R., Halnan K. E., Dische S., Saunders M. I., Cade I. S., McEwen J. B., Wiernik G., Perrins D. J., Sutherland I. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. Br J Radiol. 1978 Nov;51(611):879–887. doi: 10.1259/0007-1285-51-611-879. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES